1-3 of 3
Arthur Kudla
Close
Sort by
Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh
Journal: Blood
Blood (2022) 140 (Supplement 1): 4407–4408.
https://doi.org/10.1182/blood-2022-162738
Published: 2022
Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 177.
https://doi.org/10.1182/blood-2019-124050
Published: 2019
Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3916.
https://doi.org/10.1182/blood-2019-124034
Published: 2019